HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Triaminic Allerchews With Loratadine Slated To Launch In 2004

This article was originally published in The Tan Sheet

Executive Summary

Novartis' Triaminic children's cough/coldline will be extended in early 2004 with Allerchews, the brand's first loratadine-containing offering. The product debuted at the National Association of Chain Drug Stores Marketplace in San Diego June 8-10

You may also be interested in...



Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2

Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year

Clearasil Anti-Acne Line To Expand With Body Wash, Wipes

Boots Healthcare will add three new products to its core Clearasil line in April, including the brand's first body wash for acne, according to the firm

Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity

Geneva Pharmaceuticals initially will market the first generic competition to Schering-Plough's OTC Claritin behind pharmacy counters

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel